Ziprasidone versus risperidone in schizophrenia: An eight-week, double-blind trial with forty four-week continuation

被引：3
|
作者：
Benattia, I [1 ]
Addington, D [1 ]
Pantelis, C [1 ]
Dineen, M [1 ]
Murray, S [1 ]
机构：
[1] Pfizer Inc, New York, NY USA
来源：
SCHIZOPHRENIA RESEARCH | 2003年 / 60卷 / 01期
关键词：
D O I：
10.1016/S0920-9964(03)80431-0
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：273 / 273
页数：1
相关论文
共 50 条
  • [1] Ziprasidone vs risperidone in schizophrenia: An 8-week, double-blind trial
    Addington, D
    Pantelis, C
    Benattia, I
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S314 - S314
  • [2] Four-week, double-blind, placebo- and ziprasidone-controlled trial of lloperidone in patients with acute exacerbations of schizophrenia
    Cutler, Andrew J.
    Kalali, Amir H.
    Weiden, Peter J.
    Hamilton, Jennifer
    Wolfgang, Curt D.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2008, 28 (02) : S20 - S28
  • [3] Ziprasidone vs risperidone in schizophrenia: 52-week randomized, double-blind comparison
    Addington, D
    Pantelis, C
    Romano, SJ
    Murray, S
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 177 - 177
  • [4] A Comparison of Ziprasidone and Risperidone in the Long-Term Treatment of Schizophrenia: A 44-Week, Double-Blind, Continuation Study
    Addington, Donald E.
    Labelle, Alain
    Kulkarni, Jayashri
    Johnson, Gordon
    Loebel, Antony
    Mandel, Francine S.
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2009, 54 (01): : 46 - 54
  • [5] Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: An 8-week, double-blind, multicenter trial
    Addington, DEN
    Pantelis, C
    Dineen, M
    Benattia, I
    Romano, SJ
    JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (12) : 1624 - 1633
  • [6] Olanzapine versus ziprasidone: Results of the 28-week double-blind study in patients with schizophrenia
    Kane, JM
    Berg, P
    Thakore, J
    Naber, D
    Gattaz, WF
    Cavazzoni, P
    Walker, DJ
    Roychowdhury, SM
    Earley, W
    Breier, A
    JOURNAL OF PSYCHOPHARMACOLOGY, 2003, 17 (03) : A50 - A50
  • [7] Olanzapine versus ziprasidone: Results of a 28-week double-blind study in patients with schizophrenia
    Breier, A
    Berg, PH
    Thakore, JH
    Naber, D
    Gattaz, WF
    Cavazzoni, P
    Walker, DJ
    Roychowdhury, SM
    Kane, JM
    AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (10): : 1879 - 1887
  • [8] Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol
    Smulevich, AB
    Khanna, S
    Eerdekens, M
    Karcher, K
    Kramer, M
    Grossman, F
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 (01) : 75 - 84
  • [9] Effect of eight-week online cognitive training in Parkinson's disease: A double-blind, randomized, controlled trial
    van Balkom, Tim D.
    Berendse, Henk W.
    van der Werf, Ysbrand D.
    Twisk, Jos W. R.
    Peeters, Carel F. W.
    Hoogendoorn, Adriaan W.
    Hagen, Rob H.
    Berk, Tanja
    van den Heuvel, Odile A.
    Vriend, Chris
    PARKINSONISM & RELATED DISORDERS, 2022, 96 : 80 - 87
  • [10] Ziprasidone vs. amisulpride in treatment of negative symptoms of schizophrenia: A 12-week, double-blind trial
    Olie, JP
    Spina, E
    Benattia, I
    SCHIZOPHRENIA RESEARCH, 2002, 53 (03) : 180 - 180
12345